We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Sunday
May 17
17:00 - 18:00
A1 Plenary
Prostate cancer 1
Luca Nicosia, Italy;
Vérane Achard, France
Proffered Papers
Clinical
17:00 - 18:00
Side effects of moderately hypofractionated prostate and pelvic lymph node IMRT; results from the phase 3 PIVOTALboost randomised trial
Isabel Syndikus, United Kingdom
-1233
17:00 - 18:00
Moderately fractionated prostate radiotherapy with a focal boost: acute and preliminary late side effects from the phase 3 PIVOTALboost trial
Isabel Syndikus, United Kingdom
-1751
17:00 - 18:00
Early quality-of-life outcomes in a randomised trial of prostate radiotherapy in high-risk and N+ with moderate or extreme hypofractionation (PRIME)
Indranil Mallick, India
-1722
17:00 - 18:00
Prostate Radiotherapy In high-risk and N+ disease comparing Moderate and Extreme hypofractionation (PRIME trial, NCT03561961): Acute and 1-year Safety
Vedang Murthy, India
-1835
17:00 - 18:00
Salvage hypofractionated accelerated versus standard radiotherapy for biochemical recurrence after radical prostatectomy (SHARE): A phase 3 trial
Youngju Song, Korea Republic of
-1697
17:00 - 18:00
Elective pelvic irradiation or focal boosting in high-risk prostate cancer? Joint analysis of the POP-RT and FLAME randomized trials
Karolina Menne - Guricova, The Netherlands
-2790
17:00 - 18:00
LBA slot